Pharmaceuticals Australia

Australia Anti-Obesity Drugs Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

Australia Anti-Obesity Drugs Market Industry Trends and Forecast to 2034: Segmented by (Drug Class, Route of Administration, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Australia · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $167.2 Mn Placeholder estimate
Estimate 2025 $216.8 Mn 1.2% of the global market
Projected 2034 $2.25 Bn 938.6% Adds $2.04 Bn over 9 forecast years
CAGR 2025–2034 29.7% Faster than 96% of 186 Pharmaceuticals markets here
Key players 6 +1
  • Australia is 1.2% of the global market.
  • In APAC, the largest is China at $1.67 Bn.
  • Fastest growing: India at 30.7% a year.
  • Australia ranks 4th of 10 by size in APAC.

Market size projection

Australia

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$2.04 Bn total, 2026–2034

Year-by-year market size, 2024–2034
Anti-Obesity Drugs Market market size by year, Australia
YearMarket sizeChange that yearSince 2025
2024 (estimate) $167.2 Mn — —
2025 (base) $216.8 Mn +$49.7 Mn —
2026 (forecast) $281.2 Mn +$64.4 Mn +29.7%
2027 (forecast) $364.8 Mn +$83.5 Mn +68.2%
2028 (forecast) $473.1 Mn +$108.3 Mn +118.2%
2029 (forecast) $613.6 Mn +$140.5 Mn +183%
2030 (forecast) $795.9 Mn +$182.2 Mn +267%
2031 (forecast) $1.03 Bn +$236.4 Mn +376%
2032 (forecast) $1.34 Bn +$306.6 Mn +517.4%
2033 (forecast) $1.74 Bn +$397.6 Mn +700.8%
2034 (forecast) $2.25 Bn +$515.7 Mn +938.6%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

Australia Anti-Obesity Drugs Market Analysis at a glance
Market size, 2025$216.8 Mn placeholder estimate
Forecast, 2034$2.25 Bn placeholder estimate
Growth (CAGR), 2025–203429.7% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsDrug class, route of administration and end user (see all)
Key playersNovo Nordisk A/S, Eli Lilly and Company, Boehringer Ingelheim GmbH, Amgen Inc., Currax Pharmaceuticals and 1 more (see all)
Regulator in AustraliaTGASource: Therapeutic Goods Administration. Checked 14 Nov 2026.
Active clinical trials13 in AustraliaSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Australia. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The Australia Anti-Obesity Drugs Market Analysis Executive Summary

Anti-obesity drugs help people with obesity lose weight and keep it off by reducing appetite, increasing fullness or blocking fat absorption.

Key segments of the anti-Obesity Drugs market include drug class (GLP-1 Agonists, Dual and Triple Agonists and Lipase Inhibitors) and route of administration (Injectable and Oral).

Bar chart: Australia Anti-Obesity Drugs market size, 2024–2034, placeholder estimates. $167.2 Mn in 2024, $216.8 Mn in 2025 and $2.25 Bn in 2034, 29.7% CAGR.
Australia Anti-Obesity Drugs market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

Australia Anti-Obesity Drugs Market Dynamics

Market Growth Drivers

Rising rates of obesity and type 2 diabetes, strong clinical results for new weight-loss medicines and growing acceptance of obesity as a chronic disease are driving the anti-Obesity Drugs market. Wider insurance coverage and more doctors trained in obesity care are adding to demand.

Opportunity

Oral formulations, combination therapies and use in heart, kidney and liver disease open new growth paths for the anti-Obesity Drugs market, especially in fast-growing emerging economies.

Market Restraints

High treatment prices, limited reimbursement, supply shortages and side effects that lead some patients to stop treatment hold back the anti-Obesity Drugs market. Long-term safety data and lifestyle support are still needed for many patients.

Competitive Landscape for Anti-Obesity Drugs Market in Australia

The anti-Obesity Drugs market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Anti-Obesity Drugs Market in Australia

Anti-Obesity Drugs in Australia: rules, payment and research

Medicines must be included in the Australian Register of Therapeutic Goods (ARTG), run by the Therapeutic Goods Administration (TGA), before they can be supplied.⁠[1] Medicare pays for public hospital care and many doctor visits, and the Pharmaceutical Benefits Scheme (PBS) subsidises listed medicines.⁠[2] ClinicalTrials.gov lists 13 studies on Anti-Obesity Drugs that are recruiting, active or about to start in Australia.⁠[3] Obesity (adults): 30.6% of adults in 2024, the latest WHO figure for Australia.⁠[4]

[1] Therapeutic Goods Administration. Checked 14 Nov 2026.

[2] Pharmaceutical Benefits Scheme. Checked 14 Nov 2026.

[3] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Australia. Retrieved 12 Nov 2026.

[4] WHO Global Health Observatory, Obesity (adults) (% of adults). Retrieved 22 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for anti-Obesity Drugs. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Australia.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Anti-Obesity Drugs right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, WHO Global Health Observatory, World Bank. Fetched 22 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Anti-Obesity Drugs in context

Australia compared

  • Obesity (adults): 30.6% of adults (2024). World: 16.2% of adults (2024). 2nd highest of the 17 countries we cover in APAC.[1]
  • Health spending per person: 6,980 US$ per person (2023). World: 1,317 US$ per person (2023). Highest of the 17 countries we cover in APAC.[2]
  • Doctors: 4.09 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). Highest of the 17 countries we cover in APAC.[3]

[1] WHO Global Health Observatory, Obesity (adults) (% of adults). Retrieved 21 Nov 2026.

[2] World Bank Open Data, Health spending per person (US$ per person). Retrieved 22 Nov 2026.

[3] World Bank Open Data, Doctors (per 1,000 people). Retrieved 22 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the Anti-Obesity Drugs market in Australia?
Placeholder estimate: about $216.8 Mn in 2025, rising to about $2.25 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Anti-Obesity Drugs market in Australia growing?
Placeholder estimate: about 29.7% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Anti-Obesity Drugs market report cover?
The report splits the market by drug class (GLP-1 Agonists, Dual and Triple Agonists, Lipase Inhibitors, Combination Drugs), route of administration (Injectable, Oral) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Anti-Obesity Drugs market?
Key players include Novo Nordisk A/S, Eli Lilly and Company, Boehringer Ingelheim GmbH, Amgen Inc., Currax Pharmaceuticals and Rhythm Pharmaceuticals.
What is driving the Anti-Obesity Drugs market?
Rising rates of obesity and type 2 diabetes, strong clinical results for new weight-loss medicines and growing acceptance of obesity as a chronic disease are driving the anti-Obesity Drugs market.
Who regulates Anti-Obesity Drugs in Australia?
Medicines must be included in the Australian Register of Therapeutic Goods (ARTG), run by the Therapeutic Goods Administration (TGA), before they can be supplied. Source: Therapeutic Goods Administration. Checked 14 Nov 2026.
How is healthcare paid for in Australia?
Medicare pays for public hospital care and many doctor visits, and the Pharmaceutical Benefits Scheme (PBS) subsidises listed medicines. Source: Pharmaceutical Benefits Scheme. Checked 14 Nov 2026.
How many clinical trials on Anti-Obesity Drugs are running in Australia?
13 studies are recruiting, active or about to start in Australia, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Australia. Retrieved 12 Nov 2026.
What does WHO report for Australia?
Obesity (adults): 30.6% of adults in 2024, the latest WHO figure. Source: WHO Global Health Observatory, Obesity (adults) (% of adults). Retrieved 22 Nov 2026.
How many people in Australia are 65 or older?
18.1% of people were 65 or older in 2025. Source: World Bank Open Data, Population ages 65 and above (% of total population), from UN population estimates. Retrieved 22 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in Australia

See all

Related on obesity and diabetes

See the topic